| Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides JA O'donoghue, M Bardies, TE Wheldon Journal of Nuclear Medicine 36 (10), 1902-1909, 1995 | 493 | 1995 |
| Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu (II)-diacetyl-bis (N4-methylthiosemicarbazone) positron emission tomography: Comparative study … JA O’Donoghue, P Zanzonico, A Pugachev, B Wen, P Smith-Jones, S Cai, ... International Journal of Radiation Oncology* Biology* Physics 61 (5), 1493-1502, 2005 | 205 | 2005 |
| Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. CR Divgi, NH Bander, AM Scott, JA O'Donoghue, G Sgouros, S Welt, ... Clinical cancer research: an official journal of the American Association …, 1998 | 204 | 1998 |
| A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer N Pandit-Taskar, JA O'Donoghue, JC Durack, SK Lyashchenko, ... Clinical Cancer Research 21 (23), 5277-5285, 2015 | 201 | 2015 |
| Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer JA Carrasquillo, JA O’Donoghue, N Pandit-Taskar, JL Humm, ... European journal of nuclear medicine and molecular imaging 40, 1384-1393, 2013 | 192 | 2013 |
| First-in-humans imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting N Pandit-Taskar, MA Postow, MD Hellmann, JJ Harding, CA Barker, ... Journal of Nuclear Medicine 61 (4), 512-519, 2020 | 185 | 2020 |
| Hypoxia-induced increase in FDG uptake in MCF7 cells P Burgman, JA O’Donoghue, JL Humm, CC Ling Journal of Nuclear Medicine 42 (1), 170-175, 2001 | 175 | 2001 |
| Targeted radiotherapy using Auger electron emitters JA O'donoghue, TE Wheldon Physics in Medicine & Biology 41 (10), 1973, 1996 | 170 | 1996 |
| 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer N Pandit-Taskar, JA O’Donoghue, V Beylergil, S Lyashchenko, S Ruan, ... European journal of nuclear medicine and molecular imaging 41, 2093-2105, 2014 | 154 | 2014 |
| Implications of nonuniform tumor doses for radioimmunotherapy JA O'Donoghue Journal of Nuclear Medicine 40 (8), 1337-1341, 1999 | 148 | 1999 |
| Rationales, evidence, and design considerations for fractionated radioimmunotherapy GL DeNardo, J Schlom, DJ Buchsbaum, RF Meredith, JA O'Donoghue, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2002 | 146 | 2002 |
| Pilot trial of unlabeled and indium-111–labeled anti–prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer MJ Morris, CR Divgi, N Pandit-Taskar, M Batraki, N Warren, A Nacca, ... Clinical cancer research 11 (20), 7454-7461, 2005 | 144 | 2005 |
| First-in-human human epidermal growth factor receptor 2–targeted imaging using 89Zr-Pertuzumab PET/CT: dosimetry and clinical application in patients with breast cancer GA Ulaner, SK Lyashchenko, C Riedl, S Ruan, PB Zanzonico, D Lake, ... Journal of Nuclear Medicine 59 (6), 900-906, 2018 | 143* | 2018 |
| Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor … HJ Cho, E Ackerstaff, S Carlin, ME Lupu, Y Wang, A Rizwan, ... Neoplasia 11 (3), 247-IN3, 2009 | 141 | 2009 |
| First-in-human imaging with 89Zr-Df-IAB2M anti-PSMA minibody in patients with metastatic prostate cancer: pharmacokinetics, biodistribution, dosimetry, and lesion uptake N Pandit-Taskar, JA O’Donoghue, S Ruan, SK Lyashchenko, ... Journal of Nuclear Medicine 57 (12), 1858-1864, 2016 | 140 | 2016 |
| Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy XF Li, S Carlin, M Urano, J Russell, CC Ling, JA O'Donoghue Cancer research 67 (16), 7646-7653, 2007 | 134 | 2007 |
| Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM P Burgman, JA O'Donoghue, JS Lewis, MJ Welch, JL Humm, CC Ling Nuclear medicine and biology 32 (6), 623-630, 2005 | 129 | 2005 |
| The curability of tumours of differing size by targeted radiotherapy using 131I or 90Y TE Wheldon, JA O'Donoghue, A Barrette, AS Michalowski Radiotherapy and Oncology 21 (2), 91-99, 1991 | 121 | 1991 |
| Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning P Zanzonico, J O’Donoghue, JD Chapman, R Schneider, S Cai, S Larson, ... European Journal of Nuclear Medicine and Molecular Imaging 31, 117-128, 2004 | 120 | 2004 |
| Pharmacokinetics, biodistribution, and radiation dosimetry for 89Zr-trastuzumab in patients with esophagogastric cancer JA O'Donoghue, JS Lewis, N Pandit-Taskar, SE Fleming, H Schöder, ... Journal of Nuclear Medicine 59 (1), 161-166, 2018 | 117 | 2018 |
